Joshua Davis

In this engaging discussion, guests Steven Tong and Joshua Davis, both esteemed infectious diseases physicians, dive into the monumental SNAP trial addressing Staphylococcus aureus bacteremia. They highlight the trial's innovative design, which allows for exploring multiple clinical questions simultaneously. Key findings reveal the potential superiority of kefazolin over flucloxacillin in mortality and kidney safety outcomes. The conversation also touches on the challenges of patient enrollment and the significance of Bayesian statistics in refining treatment options. Personal anecdotes from their travels add a relatable touch to the science.